# US 2012/0269776 A1 · Productions of artificial tissues by means of tissue engineering using agarose-fibrin biomaterials

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269776 A1
- Document ID: US20120269776A1
- Status: Published application
- Kind: A1
- Application number: 13/392,445
- Filed: 2010-08-25
- Published: 2012-10-25
- Earliest claimed: 2009-08-25
- Inventors: Miguel Alaminos Mingorance; José Ignacio Muñoz Ávila; Miguel González Andrades; Antonio Campos Muñoz; Ingrid Johanna Garzón Bello
- Web page: https://patentgrep.com/patent/US20120269776A1

## CPC

- A61L 27/3804: {characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells}
- A61K 35/33: Fibroblasts
- A61K 35/36: Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells (islets of Langerhans A61K35/39)
- A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A61L 27/26: Mixtures of macromolecular compounds
- A61L 27/3691: {characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation}
- A61L 27/3813: {Epithelial cells, e.g. keratinocytes, urothelial cells}
- A61L 27/60: Materials for use in artificial skin
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0068: {General culture methods using substrates (for specific animal cell type C12N5/06)}
- C12N 5/0605: {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- C12N 5/0621: {Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N5/062)}
- C12N 5/0632: {Cells of the oral mucosa}
- C12N 5/0684: {Cells of the urinary tract or kidneys}
- C12N 5/0698: {Skin equivalents}
- A61L 2400/12: Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
- A61L 2430/16: for reconstruction of eye parts, e.g. intraocular lens, cornea
- A61L 2430/22: for reconstruction of hollow organs, e.g. bladder, esophagus, urether, uterus
- C12N 2502/094: keratinocytes
- C12N 2502/1323: Adult fibroblasts
- C12N 2506/025: from extra-embryonic cells, e.g. trophoblast, placenta
- C12N 2533/56: Fibrin; Thrombin
- C12N 2533/76: Agarose, agar-agar
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention is encompassed in the field of biomedicine and more specifically tissue engineering. It relates specifically to an in vitro method for preparing an artificial tissue, to the artificial tissue obtainable by said method and to the use of this artificial tissue to partially or completely increase, restore or replace the functional activity of a damaged tissue or organ.

## Claims

### Claim 1

An in vitro method for preparing an artificial tissue comprising:
a) adding a composition comprising fibrinogen to a sample of isolated cells,
b) adding an antifibrinolytic agent to the product resulting from step (a),
c) adding at least one coagulation factor, a source of calcium, thrombin, or any combination of the above to the product resulting from step (b),
d) adding a composition of a polysaccharide to the product resulting from step (c),
e) culturing isolated cells in or on the product resulting from step (d), and
f) inducing the nanostructuring of the product resulting from step (e).

### Claim 2 (depends on 1)

The method according to claim 1, wherein the cells of step (a) are fibroblasts or keratocytes.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method according to claim 1, wherein the fibrinogen containing composition of step (a) is blood plasma.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method according to claim 1, wherein the antifibrinolytic agent of step (b) is tranexamic acid.

### Claim at position 7

7-8. (canceled)

### Claim 9 (depends on 1)

The method according to claim 1, wherein the polysaccharide of step (d) is agarose.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method according to claim 1, further comprising a step (b2) between steps (b) and (c) wherein a protein is added.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the protein added in step (b2) is fibronectin.

### Claim 13 (depends on 1)

The method according to claim 1, further comprising a step (d2) between steps (d) and (e) which comprises adding a composition comprising a protein to the product resulting from step (d).

### Claim 14 (depends on 13)

The method according to claim 13, wherein the protein added in step (d2) is collagen.

### Claim at position 14

15-18. (canceled)

### Claim 19 (depends on 1)

The method according to claim 1, wherein the cells of step (a) and/or the cells of step (e) are autologous cells.

### Claim 20 (depends on 1)

The method according to claim 1, wherein the nanostructuring induction of step (f) comprises the dehydration and/or mechanical compression of the product resulting from step (e).

### Claim 21 (depends on 20)

The method according to claim 20, wherein the dehydration of the product resulting from step (e) comprises a method selected from the list comprising: draining, evaporation, suction, capillary pressure, osmosis or electro-osmosis.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the dehydration of the product resulting from step (e) by means of capillary pressure comprises the application of an absorbent material on the product resulting from step (e).

### Claim 23 (depends on 20)

The method according to claim 20, wherein the mechanical compression of step (f) comprises a method selected from the list comprising: application of a static load, application of a hydraulic, application of a cam, application of one or more rollers, application of a balloon, extrusion or centrifugation.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the application of a static load of step (f) comprises placing a weight on the product resulting from step (e).

### Claim 25 (depends on 1)

The method according to claim 1, wherein between step (e) and step (f) there is an additional step in which the product resulting from step (e) is exposed to air.

### Claim 26

An artificial tissue obtained by an in vitro method comprising:
a) adding a composition comprising fibrinogen to a sample of isolated cells,
b) adding an antifibrinolytic agent to the product resulting from step (a),
c) adding at least one coagulation factor, a source of calcium, thrombin, or any combination of the above to the product resulting from step (b),
d) adding a composition of a polysaccharide to the product resulting from step (c),
e) culturing isolated cells in or on the product resulting from step (d), and
inducing the nanostructuring of the product resulting from step (e).

### Claim 27

A method, for evaluating a pharmacological and/or chemical product comprising:
i) contacting a pharmacological and/or chemical product with an artificial tissue obtained by an in vitro method for preparing an artificial tissue comprising:
a) adding a composition comprising fibrinogen to a sample of isolated cells,
b) adding an antifibrinolytic agent to the product resulting from step (a),
c) adding at least one coagulation factor, a source of calcium, thrombin, or any combination of the above to the product resulting from step (b),
d) adding a composition of a polysaccharide to the product resulting from step (c),
e) culturing isolated cells in or on the product resulting from step (d), and
f) inducing the nanostructuring of the product resulting from step (e);
ii) observing the reaction produced by the pharmacological and/or chemical product in said artificial tissue; and
iii) deciding if the pharmacological and/or chemical product is suitable for animal testing.

### Claim 28

(canceled)

### Claim 29 (depends on 26)

A method to partially or completely increase, restore or replace the functional activity of a diseased or damaged tissue or organ in a subject comprising in the administration to said subject of the artificial tissue obtained by an in vitro method for preparing an artificial tissue of claim 26.

### Claim at position 26

30-37. (canceled)

### Claim 38 (depends on 26)

A pharmaceutical composition comprising the artificial tissue according to claim 26.

### Claim at position 28

39-90. (canceled)
